The anthracyclines are amongst the most active and widely used cytotoxic agents. The liver is the main route of elimination for these drugs of which doxorubicin was the first to be introduced into clinical practice. Epirubicin (4'-epidoxorubicin) is structurally closely related to doxorubicin, differing only by the orientation of the C-4'-hydroxyl group on the daunosamine sugar. This difference has an important effect on the metabolism of epirubicin (Figure 1 ). Glucuronides are formed with epirubicin at the 4' position in man (Weenan et al., 1983; Robert et al., 1985) although not in other species (Maessen et al., 1987) . By contrast, glucuronidation is not important in the metabolism of doxorubicin (Mross et al., 1988) . Epirubicin is metabolised more rapidly than doxorubicin and at equimolar doses is less toxic (Brambilla et al., 1986) .
The effect of abnormal liver biochemistry on the toxicity and pharmacokinetics of epirubicin was first described by Camaggi et al. (1982) in six patients with liver metastases. Epirubicin clearance was reduced in these patients, but this did not correlate with any single liver biochemistry test. Similar findings were described in other small studies (Camaggi et al., 1986; Robert et al., 1985; Speth et al., 1986) and the dose reductions of up to 75% based on serum bilirubin recommended by Camaggi et al. (1982) in patients with liver metastases were widely adopted (Pharmorubicin data sheet, Farmitalia Carlo Erba). Nevertheless, the poor correlation between liver biochemistry tests and anthracycline clearance has made the optimal use of the drugs difficult in patients with impaired liver function. Empirical dose adjustments may lead to ineffective treatment for some patients whilst exposing others to unacceptable toxicity.
This report describes in detail the relationship between epirubicin pharmacokinetics and liver biochemistry tests in a large, well defined group of patients with advanced breast cancer who received epirubicin as a single agent. The liver biochemistry tests used were those which are routinely available in this Unit.
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Materials and methods

Patients and treatment
Epirubicin pharmacokinetics were studied in a total of 52 women with advanced breast cancer. Patients had received no prior anthracycline treatment and pharmacokinetics studies were performed only during their first cycle of chemotherapy. None of the patients were taking drugs known to affect hepatic blood flow or drug metabolism. Treatment was given between 9.00 and 15.00 h in all cases. All patients gave written informed consent to participate in the study.
The characteristics of the patients are shown in Table I best biochemical factor predicting survival in these patients (O'Reilly et al., 1990) . Secondly, bilirubin is the basis of the currently recommended dose modifications (Pharmorubicin data sheet, Farmitalia Carlo Erba). Serum alkaline phosphatase was not used to define these groups since 36 patients had bone scans suggestive of metastatic disease. The three patient groups were as follows:
Group 1 -serum AST and bilirubin both within normal limits (22 women) Group 2 -serum AST above the upper limit of normal but a normal serum bilirubin (22 women) Group 3 -serum AST raised and bilirubin above the upper limit of normal (eight women)
Patients in group 1 were sampled after epirubicin 12.5-120 mg m-2 given as a bolus intravenous (i.v.) injection. Patients who received epirubicin 120 mg m2 were treated on a high dose epirubicin protocol (Carmo-Pereira et al., 1991) . For the remaining patients in group 1, who received epirubicin 12.5-90 mg m-2 as an i.v. bolus, the dose of chemotherapy was chosen on a random basis. The effects of treatment dose and other patient related parameters on epirubicin pharmacokinetics in this group of patients who had normal liver biochemistry tests, will be presented separately (Dobbs et al., in preparation) . Patients in whom the pharmacokinetics of the lower doses of epirubicin were being studied received the 'study' dose on day 1; where this dose was considered therapeutically inadequate the remainder of the treatment dose was given 48 h later, after completing the pharmacokinetic sampling. Subsequent chemotherapy cycles were given at standard doses as a single bolus injection every 3 weeks. The majority of patients in groups 2 and 3 received epirubicin 25 mg m-2 as an i.v. bolus given weekly. Most of the patients in groups 2 and 3 were included in a clinical study of weekly epirubicin in women with breast cancer and liver metastases the results of which have been published previously .
Liver scans are not carried out routinely in this Unit, but were undertaken in any patients with hepatomegaly or elevation of serum AST or bilirubin. Liver biopsies were not performed to confirm histologically the diagnosis of hepatic metastases.
Pharmacokinetics
Blood samples were taken from an indwelling venous cannula over the 48 h following chemotherapy. Samples were collected before treatment and at 6, 12, 15, 20, 30 and 45 min, then at 1, 2, 4, 8, 24, 30 and 48 h after the start of administration of epirubicin. Each 7 ml sample was taken into a lithium heparin tube and centrifuged, after which the separated plasma was stored at -20°C. Plasma levels of epirubicin and its six metabolites were measured by highperformance liquid chromatography using pure analytic standards provided by Farmitalia Carlo Erba (Milan, Italy). With this assay mean recovery of epirubicin is 83%, and recovery of its metabolites is 51-88%. The routine detection limit of the assay is 1 ng ml-for epirubicin, and for the metabolites ranges from 0.5-1.0 ng ml-. The within-day and day-to-day precision of the assay, as indicated by the coefficients of variation, are less than 8% both for epirubicin and for its metabolites measured over a wide range of concentrations.
Epirubicin pharmacokinetics were fitted to a 3-compartment model. The 'Pharmkit' programme (Johnson et al., 1983) was used to obtain the area under the concentrationtime curve to infinity (AUCi), the early (a), intermediate (f) and terminal half lives. The volume of distribution (Vd) and mean retention time (MRT), which is a measure of the period a molecule remains in the body, were also calculated using 'Pharmkit'. The elimination of epirubicin was expressed as drug clearance (dose/AUCi). 
Comparison of liver biochemistry tests
The clinical and biochemical characteristics of the patients in each of the three groups compared in Table I . None of the four women in group 2 with an elevated serum AST in whom liver metastases were not detected radiologically gave a history of alcohol abuse or chronic liver disease. There was no difference in age or serum creatinine between the three groups (P> 0.5). By definition, all the patients in groups 2 and 3 had a raised AST. However, serum AST was higher in the group 3 patients, whose serum bilirubin was also elevated, than it was in those of group 2 (P = 0.05). The group 1 patients with a normal AST and bilirubin had a higher median serum albumin (P = 0.003) and lower alkaline phosphatase (P<0.001) than the patients in groups 2 and 3.
Comparison ofpharmacokinetic parameters
Epirubicin clearance for patients in the three groups is shown in Figure 2 . The remaining pharmacokinetic parameters are shown in Table II .
The patients in group 2, with a raised AST but normal bilirubin, had a median epirubicin clearance which was significantly lower than that for the group 1 patients in whom both the serum bilirubin and AST were normal (P = 0.005).
the a-and P-half lives for the groups did not differ (P = 0.78
and P = 0.53 respectively). The terminal half life was, however, significantly longer in the patients with a raised AST than in those with normal liver biochemistry (P = 0.05).
There was a trend for MRT to be longer in group 2 than in group 1, but this did not reach statistical significance (P = 0.07). There was no significant difference in Vd (P = 0.IO) between the two groups. The patients in group 3, with values of both AST and bilirubin above the normal range, had a median epirubicin clearance significantly lower than that of patients in group 1 (P=0.004), but similar to that of patients in group 2 (P = 0.25). There was no difference in the a-and P-half life between patients in groups 1 and 3 (P = 0.76 and P = 0.13 respectively), but the patients in group 3 had significantly -OH group at the C-4' position on the daunosamine sugar leads to extensive glucuronidation of epirubicin and its reduced metabolite epirubicinol. In comparative studies glucuronides were detected in the plasma and urine of patients when treated with epirubicin, but not doxorubicin (Mross et al., 1988; Camaggi et al., 1988 An important question raised by this study is that of rbances of liver biochemistry were not described in whether, and how, dosage adjustments should be made when and pharmacokinetic data were presented from only using epirubicin to treat patients who have abnormal liver atients. The dose reductions they recommended, on the biochemistry. This question has not been answered satisfacof a raised serum bilirubin, were widely adopted torily by early reports (Camaggi et al., 1982; Robert et iamycin data sheet, Farmitalia Carlo Erba) although al., 1985; Speth et al., 1986) . The current study has clearly were never validated. Indeed, subsequent reports failed demonstrated a relationship between liver biochemistry, in Infirm a close relationship between abnormal liver bioparticular AST, and epirubicin pharmacokinetics. The study istry and either clinical toxicity or pharmacokinetic design, with weekly low dose chemotherapy for most neters in patients receiving doxorubicin (Brenner et al., patients, and split-dose treatment for many others, precludes Preisler et al., 1984; Preiss et al., 1987; Frenay et al., an evaluation of the relationship between liver biochemistry, l.
epirubicin pharmacokinetics and treatment toxicity or efficien epirubicin was introduced, Camaggi et al. (1982) acy. However, other studies attempting to relate anthracycibed reduced clearance in patients with liver metastases line kinetics with treatment efficacy and toxicity have had ith biliary obstruction (Camaggi et al., 1986) . As a some success. High doxorubicin levels were associated with ; , the dosage reductions recommended for epirubicin prolonged remission duration in patients with acute nonlymmorubicin data sheet, Farmitalia Carlo Erba) were phocytic leukaemia (Preisler et al., 1984) . Similarly, Robert et ir to those for doxorubicin. Several studies have failed, al. (1983) correlated early phase doxorubicin pharmacover, to demonstrate a consistent relationship between kinetics with response in patients with breast cancer. In bicin clearance and liver biochemistry tests (Camaggi et relation to treatment toxicity, raised serum transaminases 982; Robert et al., 1985; Speth et al., 1986) . These predicted reduced efficacy of scalp cooling in preventing as reported only small numbers of patients from a heteralopecia for patients treated with epirubicin (Robinson et al., bous population and the nature of the abnormalities of 1987). These data suggest that there may be a relationship biochemistry were not well defined. Because of the between anthracycline pharmacokinetics and treatment outtainty regarding the effect of liver dysfunction on epirucome although this needs clarification.
pharmacokinetics, such dose modifications have been Definitive dosage recommendations for patients with aboversial and different dosage strategies have been adoptnormal liver biochemistry will depend on demonstrating a lamaggi et al., 1982; Twelves et al., 1991) .
relationship between liver dysfunction and epirubicin phari most important finding of the current study is that a macodynamics. Nevertheless it is apparent that serum AST y available liver biochemistry test reflects consistent rather than bilirubin may be the best indicator for dose yes in epirubicin pharmacokinetics. The relationship was adjustments. In this respect, there appears to be an important gest for epirubicin clearance which is the best pharmadistinction between these two anthracyclines (Dobbs et al., etic measure of hepatic metabolism (Perrier & Grimaldi, 1991) .1-c clearance and MRT. This is due to prolongation of the terminal half-life of epirubicin in patients with a raised AST and may reflect impaired glucuronidation. These findings have potentially important implications for the treatment of patients with disturbed liver biochemistry. Firstly, in patients treated with epirubicin, AST measurements provide a more rational basis for dose reductions than the currently recommended use of serum bilirubin. Secondly, because the relationship between pharmacokinetic parameters and liver biochemistry tests is more predictive with epirubicin, this drug may be preferable to doxorubicin in these patients.
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